TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Not Specified
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

Cytek Biosciences announced preliminary Q4 2025 revenue of approximately $62 million, representing 8% year-over-year growth and 19% sequential growth. Full year 2025 revenue is expected to be approximately $201 million. The company highlighted strong growth in Services, Reagents, and Asia Pacific instrument revenue, along with improved instrument sales in the US and EMEA regions, particularly a return to positive growth in EMEA.

Insights
CTKB   positive

The company reported meaningful acceleration in Q4 growth (8% YoY, 19% QoQ), positive trends across multiple business segments (Services, Reagents, Asia Pacific), and a return to positive instrument growth in EMEA. Management expressed confidence in sustainable growth and profitability prospects in the flow cytometry market.